Charles M. Baum, Director of Acrivon Therapeutics ACRV, has filed 0 purchases and 1 sale on the open market. The latest trade was on 06/17.

CB

CB

Charles M. Baum

Director

Company

Acrivon Therapeutics ACRV

First filing

23/01/24

Trades

33 trades

Buys / sales

0 / 1

12-month net buying

No record

Last trade

06/17

FollowShare

Trading activity

6 months1 year2 years5 yearsAll

Transactions

Company	Trade type	Traded	Filed	Shares	Price	Value	Holding change
MT Mirati Therapeutics	Open-market sale	23/01/04	23/01/05	3,648 sh	$46.60	$169,996.8	−2.1%